Cyclacel Pharmaceuticals (CYCC) shoots up 11.5% in premarket trading after the firm reports...


Cyclacel Pharmaceuticals (CYCC) shoots up 11.5% in premarket trading after the firm reports positive results for its Sapacitabine drug in a phase 2 trial on MDS patients.

Comments (1)
  • Steve Rosenman
    , contributor
    Comments (765) | Send Message
     
    A $7-8 stock within 1.5 years
    13 Feb 2012, 10:35 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs